PubMed Health⌕ Search

Biomedical subjects

R W Glashan

Publications and source records attributed to R W Glashan.

9 recordsLinked to original sources
PubMed1977

Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group.

Of 48 patients with bladder tumors treated with intravesical epodyl 17 have shown a complete remission at some stage of treatment, although several have relapsed later. Partial remission occurred in 20 patients and 11 have shown no improvement or the lesions have progressed. Epodyl is used best as an adjunct to transurethral resection or diathermy of T1 bladder lesions. Even in patients who do not show complete remission epodyl may reduce the incidence of recurrence and the number of lesions. It is useful when rapid recurrence of T1 bladder tumors prevents control by resection or diathermy and it also is beneficial as an emergency measure to control hematuria. Complications are not infrequent and may be severe occasionally. Bone marrow depression has been seen in 2 patients whose bladders showed extensive carcinoma in situ.

Adult↗
PubMed1977

The clinical diagnostic value of the carcinoembryonic antigen (CEA) in haematuria.

Plasma and urinary CEA levels in patients presenting with haematuria have been studied to assess whether they facilitate the differentiation between benign and malignant urothelial conditions. Plasma CEA is of no diagnostic value although, if raised, it may suggest an invasive tumour. Urinary CEA levels are only of value in the absence of urinary infection; even then, only 37% of the cases with overt urothelial tumours had raised titres. A knowledge of the urinary CEA level, therefore, would seem to contribute little to the diagnosis of patients presenting with haematuria and all patients must still be investigated by the conventional techniques of urinary bacteriology, cytology, intravenous pyelography and cystourethroscopy.

Carcinoembryonic Antigen↗
PubMed1977

The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil.

52 patients with advanced bladder cancer, no longer controlled by conventional therapy, have been treated by combination chemotherapy with Adriamycin and 5-fluorouracil. The objective remission rate has been 40%. The morbidity of the chemotherapy has not been excessive. The response has not been related to the histological grade of the primary tumour and previous treatment. Patients with a good performance status (Karnofsky index) have responded better than those with a poor performance status.

Doxorubicin↗
PubMed1976

Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil.

The cytotoxic drug combination of adriamycin and 5-fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer. This has been achieved with minimal toxicity and on an out-patient basis. If the survival rate of patients with invasive bladder cancer is to be improved it seems likely that some form of systemic treatment will need to be added to the local measures currently in use. Further studies of different chemotherapeutic agents should help to define an effective and safe form of adjunvant therapy.

Aged↗
PubMed1975

A critical review of the management of bladder neoplasia using a modified form of Helmstein's pressure therapy.

30 patients with proven bladder malignant disease have been treated by Helmstein's hydrostatic pressure technique. Massive necrosis of tumour tissue has been shown to occur at cystoscopy, cytologically and on histological examination. Double contrast cystography can indicate reduction in tumour size within 2 weeks of treatment Haematuria is usually stopped with diminution of frequency and dysuria. This treatment is suitable for large bulky T1 tumours and advanced T4 growths where palliation is the only treatment possible but not for TI and T3 growths. Elderly and ill patients can tolerate this therapy easily and there were no serious side-effects in this series.

Abdomen, Acute↗